Target Name: SEPTIN9
NCBI ID: G10801
Review Report on SEPTIN9 Target / Biomarker Content of Review Report on SEPTIN9 Target / Biomarker
SEPTIN9
Other Name(s): SEPTIN9 variant 4 | Septin 9, transcript variant 3 | Ovarian/Breast septin | MLL septin-like fusion protein | NAPB | Septin 9, transcript variant 2 | Ovarian/breast septin | PNUTL4 | Septin 9, transcript variant 4 | MLL septin-like fusion | SeptD1 | SEPTIN9 variant 3 | Septin-9 | Septin 9, transcript variant 1 | MLL septin-like fusion protein MSF-A | MSF1 | Septin-9 (isoform a) | SEPT9_HUMAN | Septin D1 | Septin-9 (isoform c) | AF17q25 | SEPT9 | Septin-9 isoform f | SINT1 | septin D1 | MSF | Septin-9 (isoform b) | septin 9 | SEPTIN9 variant 1 | Ov/Br septin | Septin 9 | SEPTIN9 variant 2 | ovarian/breast septin

SEPTIN9: A Potential Drug Target and Biomarker

SEPTIN9 is a protein that plays a crucial role in the structure and function of hair shafts. It is a member of the SEPIN family, which is known for their ability to interact with various signaling pathways, including TGF-β and Wnt. SEPTIN9 has been shown to be involved in the regulation of cell proliferation, differentiation, and survival.

SEPTIN9 has also been implicated in the development and progression of various diseases, including cancer. For example, studies have shown that SEPTIN9 levels are decreased in various types of cancer, and that inhibition of SEPTIN9 has been shown to have therapeutic benefits in these diseases.

Due to its involvement in these processes, SEPTIN9 has potential as a drug target. By targeting SEPTIN9 with small molecules or other compounds, researchers may be able to inhibit its activity and potentially treat various diseases.

In addition to its potential as a drug target, SEPTIN9 has also been identified as a potential biomarker. The SEPIN family has been shown to be involved in the regulation of various signaling pathways, including TGF-β and Wnt. This suggests that SEPTIN9 may be involved in the regulation of these processes, and that its levels or activity may be relevant to the diagnosis or progression of certain diseases.

To further explore the potential of SEPTIN9 as a biomarker, researchers have conducted studies to determine if it can be used as a diagnostic marker for certain diseases. For example, studies have shown that SEPTIN9 levels are decreased in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that SEPTIN9 may be a useful biomarker for the diagnosis and progression of these diseases.

In addition, SEPTIN9 has also been shown to be involved in the regulation of cell survival and proliferation. This suggests that it may be involved in the development and progression of certain diseases, such as neurodegenerative disorders.

Overall, SEPTIN9 has a strong potential as a drug target and biomarker. Its involvement in various signaling pathways and its association with the development and progression of various diseases make it an attractive target for researchers to investigate further. Further studies are needed to fully understand its potential and to determine its utility as a drug and biomarker.

Protein Name: Septin 9

Functions: Filament-forming cytoskeletal GTPase (By similarity). May play a role in cytokinesis (Potential). May play a role in the internalization of 2 intracellular microbial pathogens, Listeria monocytogenes and Shigella flexneri

The "SEPTIN9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SEPTIN9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

SERAC1 | SERBP1 | SERBP1P3 | SERF1A | SERF1B | SERF2 | SERF2-C15ORF63 | SERGEF | SERHL | SERINC1 | SERINC2 | SERINC3 | SERINC4 | SERINC5 | Serine (or cysteine) proteinase inhibitor clade F | Serine palmitoyltransferase | Serine protease | Serine protease inhibitor | Serine-aspartate repeat-containing protein I-like | SERP1 | SERP2 | SERPINA1 | SERPINA10 | SERPINA11 | SERPINA12 | SERPINA13P | SERPINA2 | SERPINA3 | SERPINA4 | SERPINA5 | SERPINA6 | SERPINA7 | SERPINA9 | SERPINB1 | SERPINB10 | SERPINB11 | SERPINB12 | SERPINB13 | SERPINB2 | SERPINB3 | SERPINB4 | SERPINB5 | SERPINB6 | SERPINB7 | SERPINB8 | SERPINB9 | SERPINB9-AS1 | SERPINB9P1 | SERPINC1 | SERPIND1 | SERPINE1 | SERPINE2 | SERPINE3 | SERPINF1 | SERPINF2 | SERPING1 | SERPINH1 | SERPINI1 | SERPINI2 | SERTAD1 | SERTAD2 | SERTAD3 | SERTAD4 | SERTAD4-AS1 | SERTM1 | SERTM2 | Serum amyloid protein | SESN1 | SESN2 | SESN3 | SESTD1 | Sestrin | SET | SET1 histone methyltransferase complex | SETBP1 | SETBP1-DT | SETD1A | SETD1B | SETD2 | SETD3 | SETD4 | SETD4-AS1 | SETD5 | SETD6 | SETD7 | SETD9 | SETDB1 | SETDB2 | SETMAR | SETP14 | SETP20 | SETP22 | SETX | SEZ6 | SEZ6L | SEZ6L2 | SF1 | SF3A1 | SF3A2 | SF3A3